Dynamic Changes of Circulating Tumor DNA in Surgical Lung Cancer Patients
Completed
- Conditions
- Non-small-cell Lung CancerLung NeoplasmsCarcinoma
- Registration Number
- NCT02965391
- Lead Sponsor
- Peking University People's Hospital
- Brief Summary
Previous study showed circulating tumor DNA levels reflect the total systemic tumor burden. Circulating tumor DNA levels should decrease after complete surgery and could be increase as tumor recurrence. Few study investigated the half time of circulating tumor DNA in lung cancer patients that no criterion has been established of how to use it for surveillance.
- Detailed Description
For lung cancer patients who received surgery, multiple time of plasma will be collected before or after surgery. A series of mutations will be detected in plasma before surgery based on next generation sequencing. The positive mutation will be traced after surgery and in follow up.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- Suspected lung cancer before surgery
- No malignant tumor history within the past 5 years
- The pulmonary nodule is not pure ground glass opacity
- Patients must have given written informed consent
Exclusion Criteria
- Multiple primary lung cancer
- R1,R2 resection
- Histology confirmed not non-small cell lung cancer
- Unqualified blood samples
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Half-life of circulating tumor DNA after surgery 3 months
- Secondary Outcome Measures
Name Time Method Correlation of circulating tumor DNA level after surgery with clinical features 3 months The variation of circulating tumor DNA level before and after surgery 3 months Correlation of circulating tumor DNA level after surgery with tumor recurrence 3 years
Trial Locations
- Locations (1)
Peking University People's Hospital
🇨🇳Beijing, Beijing, China